Life Science News

RSS

INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar

INmune Bio Inc. (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

From INmune Bio 22 Oct 2026

Stem cell therapies may need new protein quality control standards

Current Good Manufacturing Practice (GMP) standards for cell therapies assess identity, viability, sterility, and genetic stability. For extracellular vesicle (EV) products, Minimal Information for Studies of Extracellular Vesicles (MISEV2023) guidance adds particle size, concentration, markers, morphology, contaminants, endotoxin, and assays.

22 Oct 2026

Penn State study identifies new regulator of jumping genes

As much as half of the human genome is composed of so-called "jumping genes." These DNA sequences can make copies of themselves that are inserted back into the genome at another location, playing a significant functional role in creating the diversity that drives evolution and in regulating how other genes are turned on or off.

21 Oct 2026

Study shows circadian rhythms vary across different cell types

Biological clocks coordinate the spatiotemporal organization of metabolism with diurnal time cues, and bulk-tissue RNA sequencing studies in mammals have revealed widespread circadian (about 24 h) gene expression in mice and non-human primates.

21 Oct 2026

Greenwood Genetic Center researcher wins major grant to explore cellular metabolism and glycosylation

Heather Flanagan-Steet, PhD, Associate Director of Research at the Greenwood Genetic Center (GGC), has received a $1.4 million, five-year Maximizing Investigators' Research Award (MIRA) R35 grant from the National Institutes of Health's National Institute of General Medical Sciences.

21 Oct 2026

Cell Painting method reveals drug differences in 3D cancer cells

Researchers at Uppsala University have adapted Cell Painting, a widely used imaging method in drug discovery, to look at individual cells inside small 3D clusters of cancer cells.

21 Oct 2026

All-in-one solution for continuous microbial monitoring without production interruptions

Particle Measuring Systems (PMS), a global leader in contamination monitoring solutions, today announced the launch of the BioCapt® Single-Use STS Microbial Monitor, a sterile transfer solution that enables the introduction of viable air monitoring consumables into isolators and Restricted Access Barrier Systems (RABS) without requiring additional decontamination activities.

From Particle Measuring Systems 21 Oct 2026

Takara Bio USA partners with SPT Labtech to deliver automation-ready NGS library preparation technologies

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., and SPT Labtech today announced their partnership to deliver validated, automated library preparation workflows that combine Takara Bio next-generation sequencing (NGS) library preparation chemistries with SPT Labtech's firefly liquid handling platform.

From Takara Bio USA, Inc. 21 Oct 2026

ScionxBio announces collaboration to develop long-acting xRNA therapeutics

ScionxBio (the "company", operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio's proprietary TERA® platform.

From ScionxBio 21 Oct 2026

Paternal age may influence sex-specific gene expression changes in embryos

When genes are "expressed," it is like reading an instruction manual to create things the body needs - such as proteins or RNA.

20 Oct 2026

Novel "Raman genome" concept enables rapid tracking of viruses

A research team led by Distinguished Professor Giuseppe Pezzotti at the Biomedical Engineering Center, Kansai Medical University, has demonstrated that differences in the molecular structures of viral RNA can be captured as "Raman barcodes," enabling the identification of 20 SARS-CoV-2 variants and subvariants.

20 Oct 2026

Scientists find a way to boost the body's natural viral defenses

Washington State University researchers have discovered how to "crank up" a natural defense system in the body to combat viral infection, potentially opening a new door for treating virus infections, cancer, neurological disorders and other diseases.

20 Oct 2026

S2N.Bio commences technology transfer of Alzheimer’s cell therapy to Cell Therapies’ Melbourne GMP facility

Cell Therapies Pty Ltd and S2N.Bio (“S2N”) have commenced technology transfer of S2N’s cell therapy candidate for Alzheimer’s disease. The transfer will enable GMP manufacture of clinical trial material for S2N’s first-in-human study in Australia.

20 Oct 2026

Discovery of new bacteria opens fresh avenues for prostate cancer research

University of East Anglia researchers have discovered the genetic blueprints of 18 new bacterial species collected from prostate cancer patients.

20 Oct 2026

New gene-editing platform gives doctors control over cell therapies

An Australian clinician-led research team has developed a gene-editing platform that could give doctors more control over cell therapies, making them more practical for patients with complex immune conditions.

20 Oct 2026

Researchers capture clear images of complex cancer drug building enzyme

A joint research group led by Ryo Tanifuji and Hiroki Oguri from the University of Tokyo and Yoshikazu Tanaka from Tohoku University has successfully visualized SacC, an enzyme that plays a key role in building the complex five-ring core of safracin B.

19 Oct 2026

Researchers use AI to identify early-stage inhibitors for antiviral therapy

Viral infections can be difficult to treat as viruses evolve rapidly, allowing them to develop resistance to drugs designed to attack viral proteins directly.

19 Oct 2026

Silicone droplets or protein aggregates? Vision Analytical’s Raptor 1788 answers the prefilled syringe particle question at PDA Universe of Pre-Filled Syringes and Injection Devices 2026

Optimize subvisible particle analysis in prefilled syringes with the Raptor 1788, featuring high-resolution imaging and non-destructive testing capabilities.

From Vision Analytical Inc. 19 Oct 2026

Invisible no more: New treatment avenue unlocked for deadliest lung cancer

Researchers have uncovered a previously overlooked immune cell that can recognize and kill small cell lung cancer, the most aggressive form of the disease globally.

16 Oct 2026

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology.

16 Oct 2026